Publications by authors named "Carole Longson"

Claim this Profile
A
Antimicrobial resistance: a light at the end of the tunnel?
Colm T Leonard, Derek Ward, Carole Longson

Lancet· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Drugs Fund: the bigger picture.
Carole M Longson, Linda J Landells, Elisabeth George, Meindert Boysen, Andrew Dillon

BMJ· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NICE supports allowing technology assessment bodies to provide advice to drug industry.
Carole Longson, Nick Crabb, Leeza Osipenko

BMJ· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HTAi Policy Forum: keeping HTA on track.
Carole Longson

Int J Technol Assess Health Care· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the Role and Evidence Expectations of Health Technology Assessment and Coverage/Payer Bodies: What Are They Looking for, and How and Why Does This Differ From What Regulators Require?
Chris Henshall, Lloyd Sansom, Hans-Georg Eichler, Alexandre Lemgruber, Carole Longson

Ther Innov Regul Sci· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How can we get high quality routine data to monitor the safety of devices and procedures?
Bruce Campbell, Andrew C Stainthorpe, Carole M Longson

BMJ· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
At the center of health care policy making: the use of health technology assessment at NICE.
Andrew J Stevens, Carole Longson

Med Decis Making· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Journal of the Royal Society of Medicine. Foreward by the Director of the Centre for Health Technology Evaluation.
Carole Longson

J R Soc Med· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A little learning: reflections on 10 years of NICE technology appraisals.
Carole M Longson

Health Econ· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
Rebecca Trowman, Helen Chung, Carole Longson, Peter Littlejohns, Peter Clark

Clin Cancer Res· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide for the treatment of relapsed multiple myeloma.
Elangovan Gajraj, Helen Chung, Meindert Boysen, David B Barnett, Carole Longson

Lancet Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10 years of NICE: still growing and still controversial.
Peter Littlejohns, Sarah Garner, Nick Doyle, Fergus Macbeth, David Barnett, Carole Longson

Lancet Oncol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NICE does consider patient views.
Marcia Kelson, Carole Longson, Peter Littlejohns

BMJ· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib for the treatment of non-small-cell lung cancer.
Meindert Boysen, Carole Longson, Andrew Stevens

Lancet Oncol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NICE Methodology for Technology Appraisals: cutting edge or tried and trusted?
Louise Longworth, Carole Longson

Pharmacoeconomics· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab for follicular non-Hodgkin lymphoma.
Elangovan Gajraj, Helen Chung, Carole Longson, Andrew Stevens

Lancet Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac resynchronisation therapy for the treatment of heart failure: NICE technology appraisal guidance.
David Barnett, Seren Phillips, Carole Longson

Heart· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK.
David Barnett, Andrew Stevens, Carole Longson

Lancet Oncol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving patient access to novel medical technologies in Europe.
Peter Kearney, Graham Stokoe, Günter Breithardt, Carole Longson, Jean Marco

Eur Heart J· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Peter Littlejohns, David Barnett, Carole Longson,

Lancet Oncol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis